Open Access

Potential of osteopontin in the management of epithelial ovarian cancer

Katarina Cerne
Katarina Cerne
, 
Benjamin Hadzialjevic
Benjamin Hadzialjevic
, 
Erik Skof
Erik Skof
, 
Ivan Verdenik
Ivan Verdenik
 and 
Borut Kobal
Borut Kobal
   | Jan 31, 2019
Radiology and Oncology's Cover Image
About this article
Previous Article
Next Article
Cite
Article Category: Research Article
Published Online: Jan 31, 2019
Page range: 105 - 115
Received: Sep 07, 2018
Accepted: Dec 27, 2018
DOI: https://doi.org/10.2478/raon-2019-0003
© 2019 Katarina Cerne, Benjamin Hadzialjevic, Erik Skof, Ivan Verdenik, Borut Kobal published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Receiver operating characteristic (ROC) curve for the diagnosis of ovarian cancer. The predictive performance of preoperative serum soluble osteopontin (sOPN) concentration (A) and ascites sOPN concentration (B). AUC = area under the curve
Receiver operating characteristic (ROC) curve for the diagnosis of ovarian cancer. The predictive performance of preoperative serum soluble osteopontin (sOPN) concentration (A) and ascites sOPN concentration (B). AUC = area under the curve

Figure 2

Kaplan-Meier survival curves. Overall survival (OS) according to preoperative soluble osteopontin (sOPN) concentrations in serum (A) and in ascites (B). Serum sOPN concentrations: group 1 ≤ 75.39 ng/ml (blue line) and group 2 > 75.39 ng/ml (green line). Ascites sOPN concentrations: group 1 ≤ 2729 ng/ml (blue line) and group 2 > 2729 ng/ml (green line).
Kaplan-Meier survival curves. Overall survival (OS) according to preoperative soluble osteopontin (sOPN) concentrations in serum (A) and in ascites (B). Serum sOPN concentrations: group 1 ≤ 75.39 ng/ml (blue line) and group 2 > 75.39 ng/ml (green line). Ascites sOPN concentrations: group 1 ≤ 2729 ng/ml (blue line) and group 2 > 2729 ng/ml (green line).

Figure 3

Progression-free survival (PFS) according to preoperative soluble osteopontin (sOPN) concentrations in serum (A) and in ascites (B). Serum sOPN concentrations: group 1 ≤ 75.39 ng/ml (blue line) and group 2 > 75.39 ng/ml (green line). Ascites sOPN concentrations: group 1 ≤ 2729 ng/ml (blue line) and group 2 > 2729 ng/ml (green line).
Progression-free survival (PFS) according to preoperative soluble osteopontin (sOPN) concentrations in serum (A) and in ascites (B). Serum sOPN concentrations: group 1 ≤ 75.39 ng/ml (blue line) and group 2 > 75.39 ng/ml (green line). Ascites sOPN concentrations: group 1 ≤ 2729 ng/ml (blue line) and group 2 > 2729 ng/ml (green line).

Figure 4

Association of surgical outcome and soluble osteopontin (sOPN) concentrations in serum (A) and ascites (B) at primary operation. Group 1: patients with complete (R0) and optimal (R1) cytoreduction. Group 2: patients with suboptimal (R2) cytoreduction and unresectable disease. *p < 0.05
Association of surgical outcome and soluble osteopontin (sOPN) concentrations in serum (A) and ascites (B) at primary operation. Group 1: patients with complete (R0) and optimal (R1) cytoreduction. Group 2: patients with suboptimal (R2) cytoreduction and unresectable disease. *p < 0.05

Figure 5

Correlation between serum cancer antigen 125 (CA125) normalisation after platinum-based chemotherapy and soluble osteopontin (sOPN) concentrations in preoperative serum (A) and ascites (B).
Correlation between serum cancer antigen 125 (CA125) normalisation after platinum-based chemotherapy and soluble osteopontin (sOPN) concentrations in preoperative serum (A) and ascites (B).

Figure 6

Comparison of soluble osteopontin (sOPN) concentrations in serum during treatment. Epithelial ovarian cancer (EOC) group - sOPN concentration: T0-preoperative, T1-after primary (debulking) surgery and T2–3 to 6 months after systemic chemotherapy. Control group (patients with benign gynaecological pathology) – sOPN concentrations: T0-preoperative and T2–3 to 6 months after surgery.
Comparison of soluble osteopontin (sOPN) concentrations in serum during treatment. Epithelial ovarian cancer (EOC) group - sOPN concentration: T0-preoperative, T1-after primary (debulking) surgery and T2–3 to 6 months after systemic chemotherapy. Control group (patients with benign gynaecological pathology) – sOPN concentrations: T0-preoperative and T2–3 to 6 months after surgery.

Figure 7

Association of tumour size and soluble osteopontin (sOPN) concentrations in preoperative serum (A) and ascites (B). Group 1: patients with tumour size ≤ 10 cm. Group 2: patients with tumour size > 10 cm. *p < 0.05
Association of tumour size and soluble osteopontin (sOPN) concentrations in preoperative serum (A) and ascites (B). Group 1: patients with tumour size ≤ 10 cm. Group 2: patients with tumour size > 10 cm. *p < 0.05

Characteristics of control patients

Parameters Data
Control group
Number of patients 34
Age (years, value ± SEM) 41.97 ± 1.68
Age range (years) 21-69
Elevated CA125 (U/mL)
n (%) 0
Value (mean ± SEM) NA
sOPN (ng/mL)
Serum (mean ± SEM) 28.12 ± 2.10
Peritoneal fluid (mean ± SEM) 132.02 ± 7.85
Benign diagnosis, n (%)
Benign ovarian cyst 6 (17 %)
Myoma of uterus 21 (62 %)
Pelvic pain, sterilisation 5 (15 %)
Preventive adnexectomy 2 (6 %)
Peritoneal fluid (mL)
Volume (mean ± SEM) 8.04 ± 1.22

Comparison between ovarian cancer patients’ characteristics who underwent primary debulking surgery and those considered candidates for neoadjuvant chemotherapy (= diagnostic laparoscopy as primary event)

Data
Parameters Primary event: Debulking surgery Primary event: Diagnostic laparoscopy
Number of patients 13 18
Age (years, value ± SEM) 57.61 ± 3.27 62 ± 2.45
Age range (years) 41-76 45-85
Elevated CA125 (U/mL)
n (%) 13 (100 %) 18 (100 %)
Value (mean ± SEM) 3936 ± 1568 3904 ± 1972
sOPN (ng/mL)
Serum (mean ± SEM) 70.48 ± 9.95 102 ± 11.53
Ascites (mean ± SEM) 2154 ± 479.7 4515 ± 657.3
Histological type, n (%)
Serous 10 (77 %) 17 (94 %)
Endometrioid 2 (15 %) 1 (6 %)
Serous + clear cell 1 (8 %) 0 (0 %)
FIGO stage, n (%)
IIIB 1 (8 %) 0 (0 %)
IIIC 11 (84 %) 11 (61 %)
IV 1 (8 %) 7 (39 %)
Histological grade, n (%)
G1 0 (0 %) 2 (11 %)
G2 5 (38 %) 7 (39 %)
G3 8 (62 %) 9 (50 %)
Ascites (mL)
Volume (mean ± SEM) 1779 ± 728.4 3916 ± 614.7
Resection, n (%) *
R0 5 (38 %) 9 (50 %)
R1 5 (38 %) 1 (6 %)
R2 3 (24 %) 0 (0 %)
Unresectable 0 (0 %) 8 (44 %)
eISSN:
1581-3207
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed